Showing 4271-4280 of 5771 results for "".
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion
- Accure Therapeutics Enrolls First Patient in Phase 2 Clinical Trial on Acute Optic Neuritishttps://modernod.com/news/accure-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-on-acute-optic-neuritis/2478923/Accure Therapeutics announced it has enrolled the first patient in its ACUITY phase 2 clinical trial in patients with acute optic neuritis (AON). A total of 36 patients will be enrolled in two randomized parallel groups. They will be followed for 6 months to measure and assess safety and prelimin
- Allergan Submits New Drug Application for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-submits-new-drug-application-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478915/Allergan announced that it has submitted a new drug application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021. The NDA is based primarily on data from two phase 3 G
- New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic Phasehttps://modernod.com/news/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-beyond-acute-disease-into-chronic-phase/2478913/Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the North American Neuro-Ophthalmology Society (NANOS) 2021 Virtual Annual Meeting. Findings demonstrate that TED not only has a significant burden on patients during the acute (activ
- VRmagic Eyesi Slit Lamp Fundoscopy Module Launched in the UKhttps://modernod.com/news/vrmagic-eyesi-slit-lamp-fundoscopy-module-launched-in-the-uk/2478908/Haag-Streit UK has announced the launch of the Eyesi Slit Lamp Fundoscopy Module in the UK. VRmagic’s new Fundoscopy Module can be mounted to the
- Bausch + Lomb Launches Alaway Preservative Free Antihistamine Eye Dropshttps://modernod.com/news/bausch-lomb-launches-alaway-preservative-free-antihistamine-eye-drops/2478902/Bausch + Lomb announced the US launch of Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. Bausch + Lomb says Alaway is the first and only over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the FDA.
- AcuFocus Submits US Premarket Approval Application to the FDA for Its IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-submits-us-premarket-approval-application-to-the-fda-for-its-ic-8-small-aperture-iol/2478903/AcuFocus announced that it has submitted a premarket approval (PMA) application to the FDA for its IC-8 small aperture IOL. The IC-8 IOL is an aspheric monofocal lens that features an embedded filter with a small central aperture. Using wavefront-filtering, small aperture optics, the lens is desi
- Allergan Launches Refresh Digital Lubricant Eye Dropshttps://modernod.com/news/abbvie-launches-refresh-digital-lubricant-eye-drops/2478901/Allergan announced the over-the-counter (OTC) launch of Refresh Digital, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. Refresh Digital features proprietary HydroCell technology that supports all three layers of the te
- Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical Trialshttps://modernod.com/news/asclepix-therapeutics-partners-with-notal-vision-on-home-oct-remote-monitoring-in-dme-and-amd-clinical-trials/2478900/Notal Vision announced that the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision Diagnostic Clinic to support AsclepiX’s AXT107 phase 1 clinical trial program. The
- Re-Vana Therapeutics Names New Members to the Executive Teamhttps://modernod.com/news/re-vana-therapeutics-names-new-members-to-the-executive-team/2478897/Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a br